• Kalbe Farma's net sales rose 12% to IDR 29 trillion in 9M26, with organic growth driven by volume.
• Prescription pharmaceuticals' gross profit margin fell to 46.4% from 50.4% due to raw materials and product mix.
• Consumer health net sales climbed 10% to IDR 3.95 trillion.
• The company is expanding its insulin and cell-therapy businesses while strengthening its vaccine portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PT Kalbe Farma Tbk published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.